The Nasdaq Stock Market granted Citius Oncology an extension until April 19, 2027, to demonstrate compliance with the $1.00 per share minimum bid price requirement for continued listing on the Nasdaq Capital Market. If the stock closes at or above $1.00 for ten consecutive business days before that date, the company will regain compliance. Failure to meet this threshold by April 19, 2027, will result in a delisting notice, though the company retains the right to appeal to a Nasdaq hearings panel. The filing notes that the listing remains active during this period and the company is evaluating options to restore compliance. Citius Oncology operates as a clinical-stage biopharmaceutical company focused on developing oncology treatments.
